Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) is implicated in protein degradation pathways.
• Telomerase reverse transcriptase (TERT) is a key component of telomere maintenance.
• The interplay between DYRK2 and TERT in cancer progression is an area of active research.

Purpose of the Study:

• To investigate the expression of DYRK2 and TERT in early breast cancer.
• To evaluate DYRK2 and TERT as potential biomarkers for predicting breast cancer recurrence.
• To correlate their expression with clinicopathological factors and patient survival.

Main Methods:

• Immunohistochemical analysis was performed on tumor samples from 221 early breast cancer patients.
• DYRK2 and TERT expression levels were quantified.
• Statistical analyses were used to correlate protein expression with clinicopathological data and disease-free survival.

Main Results:

• DYRK2 and TERT were expressed in 26% and 39% of patients, respectively.
• No significant correlation was found between DYRK2/TERT expression and clinicopathological factors.
• DYRK2-positive patients showed better disease-free survival (p=0.032), while TERT-positive patients had poorer disease-free survival (p=0.023).
• The combined DYRK2-positive/TERT-negative group demonstrated significantly better disease-free survival (p=0.006).

Conclusions:

• DYRK2 and TERT expression levels serve as independent predictors of recurrence in early breast cancer.
• The combined assessment of DYRK2 and TERT expression may offer a powerful tool for patient stratification.
• This finding could aid in tailoring treatment strategies for breast cancer patients.